March 17, 2009 - Clinical pharmacology company Cetero Research and centralized cardiac testing company Cardiocore announced today a global strategic alliance to optimize the design, conduct and reporting of cardiac safety studies.
The alliance provides clinical trial sponsors direct access to the world’s most experienced team of Thorough QT (TQT) scientists, unparalleled subject enrollment and bed capacity, integrated study management and accelerated data delivery, the companies said. The partnership’s turnkey offering also streamlines sponsors’ vendor selection, quality evaluation and contracting processes.
“When selecting a clinic and core lab for cardiac safety trials, customers consistently tell us their most important needs are hands-on experts, top-quality facilities and seamless project controls,” said Dr. Jerry Merritt, CEO of Cetero Research. “By creating the first true integration between a top clinical pharmacology CRO and a top core lab, the Cetero-Cardiocore alliance is able to provide clients with a turnkey solution to their cardiac safety needs, with one contract, one project manager, and one final report.”
Cardioscore said its solution has a fully integrated study design, clinical conduct, project oversight, data interpretation and expert reporting.
Cetero and Cardiocore have validated the success of their unified service delivery through the joint conduct of TQT and other cardiac safety studies performed since the publication of the E-14 Guidance for Industry. Together, the two organizations offer unmatched expertise in clinical pharmacology, bioanalytical services, cardiac safety consulting, and electrocardiographic analyses. Their client base includes large multinational pharmaceutical companies, mid-tier specialty drug developers and emerging biotechnology firms.
For more information: www.cetero.com, www.cardiocore.com
November 18, 2024 
